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Background: Recent evidence suggests that the prostate cancer (PCa)-specific up-regulation of certain genes such
as AMACR, EZH2, PSGR, PSMA and TRPM8 could be associated with an aberrant expression of non-coding
microRNAs (miRNA).
Methods: In silico analyses were used to search for miRNAs being putative regulators of PCa-associated genes. The
expression of nine selected miRNAs (hsa-miR-101, -138, -186, -224, -26a, -26b, -374a, -410, -660) as well as of the
aforementioned PCa-associated genes was analyzed by quantitative PCR using 50 malignant (Tu) and matched
non-malignant (Tf) tissue samples from prostatectomy specimens as well as 30 samples from patients with benign
prostatic hyperplasia (BPH). Then, correlations between paired miRNA and target gene expression levels were analyzed.
Furthermore, the effect of exogenously administered miR-26a on selected target genes was determined by quantitative
PCR and Western Blot in various PCa cell lines. A luciferase reporter assay was used for target validation.
Results: The expression of all selected miRNAs was decreased in PCa tissue samples compared to either control group
(Tu vs Tf: -1.35 to -5.61-fold; Tu vs BPH: -1.17 to -5.49-fold). The down-regulation of most miRNAs inversely correlated
with an up-regulation of their putative target genes with Spearman correlation coefficients ranging from -0.107 to
-0.551. MiR-186 showed a significantly diminished expression in patients with non-organ confined PCa and initial
metastases. Furthermore, over-expression of miR-26a reduced the mRNA and protein expression of its potential target
gene AMACR in vitro. Using the luciferase reporter assay AMACR was validated as new target for miR-26a.
Conclusions: The findings of this study indicate that the expression of specific miRNAs is decreased in PCa and
inversely correlates with the up-regulation of their putative target genes. Consequently, miRNAs could contribute to
oncogenesis and progression of PCa via an altered miRNA-target gene-interaction.
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Prostate cancer (PCa) is the second most frequent tumor
and the sixth leading cause of cancer-related death among
males worldwide [1]. Even though early detection of PCa
has dramatically increased since the introduction of serum
prostate-specific antigen (PSA) measurement, the lack
of specificity of PSA as a tumor marker results in a high
rate of unnecessary biopsies [2]. Consequently, various at-
tempts have been made to identify new biomarkers that* Correspondence: kati.erdmann@uniklinikum-dresden.de
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unless otherwise stated.allow the detection of PCa at an early stage as well as the
discrimination between benign and malignant alterations
of the prostate. In previous studies, we have analyzed se-
lected transcript markers such as AMACR, EZH2, PSGR,
PSMA and TRPM8 among others in PCa tissue speci-
mens. All of these markers were significantly up-regulated
in PCa tissue compared to non-malignant prostate tissue
and thus, could be of clinical importance for diagnostic
purposes [3-6].
Originally identified as an enzyme that is involved in
the metabolism of fatty acids AMACR (alpha-methylacyl-
CoA racemase) is also highly over-expressed in PCa and
its immunohistochemical detection is currently used byal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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It has been shown that AMACR can modify the growth
of PCa cells in an androgen-independent manner [9].
EZH2 (enhancer of zeste homolog 2) is a member of the
polycomb-group family and functions as a transcrip-
tional repressor [10]. As an oncogene it is frequently
up-regulated in hormone-refractory metastatic PCa sug-
gesting a critical role for EZH2 in disease progression
[11]. PSGR (prostate-specific G-protein coupled receptor;
synonym: olfactory receptor, family 51, subfamily E, mem-
ber 2 (OR51E2)) is a member of the G-protein-coupled ol-
factory receptor family that is predominantly expressed in
the human prostate [12,13]. PSGR has been described to
be over-expressed in PCa tissue [13,14] and a multiplexed
model based on the detection of PSGR and PCA3 (prostate
cancer gene 3) in urine improved the specificity for PCa
prediction [15]. PSMA (prostate-specific membrane anti-
gen; synonym: folate hydrolase 1 (FOLH1)) is a cell-surface
antigen with abundant and virtually universal expression in
PCa which increases as the cancer progresses [16,17]. Since
PSMA is an antigen that is highly specific for PCa tissue its
targeting can be used for in vivo imaging and immunother-
apy of PCa [18,19]. TRPM8 (transient receptor potential
cation channel, subfamily M, member 8; synonym: Trp-p8)
is involved in the regulation of the intracellular Ca2+ con-
centration and exhibits an elevated expression in PCa
[20,21]. TRPM8 is an androgen-responsive gene and essen-
tial for the survival of PCa cells [22].
The tumor-specific up-regulation of the aforementioned
genes suggests a functional role for these genes in the de-
velopment and progression of PCa. However, the genetic
and epigenetic mechanisms that lead to their up-regulation
are mainly unknown. The demonstrated abnormal expres-
sion patterns could be associated with a deregulation of
microRNA (miRNA) expression. MiRNAs are small (~22
nucleotides) non-coding RNAs that are involved in a var-
iety of oncogenic pathways [23]. As post-transcriptional
regulators they bind to the 3′-untranslated region (3′UTR)
of their target mRNA resulting in either translational re-
pression or mRNA degradation [23,24]. Depending on
their target genes miRNAs can either function as onco-
genes or tumor-suppressors [24].
It has been reported that miRNAs have distinct expres-
sion profiles in various human cancers [25-27]. Several
profiling studies have also shown that the expression of
miRNAs is commonly altered in PCa compared to normal
tissues [25,28-33]. A deregulation of the miRNA expres-
sion consequently leads to an altered interaction with their
respective mRNA targets and thus, promotes abnormal
cellular functions [34,35]. To evaluate the influence of
miRNAs on the onset or progression of PCa it is therefore
of utmost importance to identify and analyze potential in-
teractions between PCa-associated genes and their puta-
tive miRNA regulators. However, only few studies haveassessed such a connection between a miRNA deregula-
tion and an up-regulation of PCa-specific genes. Of the
PCa-associated genes investigated in this study a miRNA-
mediated regulation has been reported only for EZH2 so
far [36-40].
The aim of this study was to identify miRNAs that
could potentially regulate the expression of genes that
are known to be up-regulated in PCa. Subsequently, the
expression levels of both the candidate miRNAs and the
PCa biomarkers were analyzed in malignant and non-
malignant prostate tissues. Furthermore, the miRNA ex-
pression data were evaluated with regard to a potential
correlation with the expression levels of the PCa-associated
genes as well as with clinicopathological parameters. In an
initial assessment the influence of exogenously adminis-
tered miR-26a on the mRNA and protein expression of its
known target EZH2 as well as its potential new target gene
AMACR was investigated in various PCa cell lines. Subse-
quently, target validation for miR-26a was conducted by a
luciferase reporter assay.
Methods
In silico miRNA prediction
To identify miRNAs that might target the PCa-associated
genes AMACR, EZH2, PSGR, PSMA, and TRPM8 the
following publicly available bioinformatic prediction pro-
grams as well as a database of experimentally suppor-
ted miRNA targets were used: TargetScanHuman v5.1,
TargetScanS, PicTar (based on conservation in mammals),
MicroCosm Targets, microRNA.org (release 03/2009),
Human miRNA Targets (optimized intersection: PicTar,
TargetScanS), DIANA microT v3.0 and DIANA TarBase
v5.0 (Additional file 1: Table S1). For subsequent analyses
miRNAs were considered that were predicted (i) by mul-
tiple algorithms per gene or (ii) for more than one gene.
Tissue specimens
Fresh-frozen malignant (tumor: Tu) and corresponding
non-malignant (tumor-free: Tf ) specimens from 50 pa-
tients with primary PCa who underwent radical prosta-
tectomy as well as 30 samples from patients with benign
prostatic hyperplasia (BPH) were used for mRNA and
miRNA expression analyses. The BPH samples were ob-
tained from patients undergoing radical cystectomy for
bladder cancer or prostatic adenomectomy for BPH treat-
ment. None of the PCa patients received neoadjuvant hor-
monal treatment. The clinicopathological data of the
patients are given in Table 1. After removal of the prostate
gland, the tissue was roughly cut into regions based on its
normal and tumor suspicious appearance and then cryo-
preserved in liquid nitrogen. For further analyses, cryosec-
tions of available tissues were prepared and the tumor
cell amount of all samples was estimated by an experi-
enced pathologist on hematoxylin-eosin stained serial
Table 1 Clinicopathological data of the patients
Parameter PCa BPH
Total patient number 50 30
Age at surgery [years]
Median (range) 65 (49 – 78) 72 (50 – 86)
Pre-operative PSA [ng/ml]
Median (range) 10.2 (2.8 – 113.0) 2.6 (0.2 – 46.2)
n (%)
Tumor stage
pT2 (organ-confined) 23 (46%) -
pT3 + 4 (nonorgan-confined) 27 (54%) -
Gleason score
< 7 (low) 16 (32%) -
7 (intermediate) 19 (38%) -
> 7 (high) 15 (30%) -
Lymph node status
N0 43 (86%) -
N+ 7 (14%) -
Distant metastases at prostatectomy
M0 46 (92%) -
M+ 4 (8%) -
Initial metastases
N0M0 40 (80%) -
N+/M+ 10 (20%) -
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of the Tu samples was ≥50% and that of Tf and BPH sam-
ples 0%. Tissue collection and analysis was approved by
the internal review board of the Technical University of
Dresden (EK194092004 and EK195092004). Written in-
formed consent was obtained from each patient.
Cell lines
The human PCa cell lines DU-145 (HTB-81), PC-3
(CRL-1435) and LNCap (CRL-1740) were obtained from
the American Type Culture Collection (ATCC) and
maintained at standard conditions (37°C, humidified at-
mosphere containing 5% CO2) without antibiotics. DU-
145 and PC-3 cells were cultured in DMEM (4.5 g/l glu-
cose) supplemented with 10% fetal bovine serum (FBS),
1% 1 M HEPES buffer and 1% MEM non-essential amino
acids, whereas LNCap cells were grown in RPMI-1640 in-
cluding 10% FBS and 1% MEM non-essential amino acids
(all from Life Technologies).
MiRNA mimics, siRNAs and transient transfection
The mimic for miR-26a (PM10249) and the Pre-miR
Negative Control #1 (miR-CON) were obtained from Life
Technologies. Specific small interfering RNAs (siRNAs)
directed against AMACR (siR-AMACR; sense: GAGAUUUAUCAGCUUAACU, antisense: AGUUAAGCUGAU
AAAUCUC) and EZH2 (siR-EZH2; sense: CACAAGU
CAUCCCAUUAAA, antisense: UUUAAUGGGAUGACU
UGUG) as well as the negative control siRNA (siR-CON;
SR-CL000-005) were synthesized by Eurogentec. Cells
were washed with PBS and transfected for 4 h in serum-
free OptiMEM (Life Technologies) using DOTAP liposomal
transfection reagent (Roche) according to the manufac-
turer’s instructions. The final concentrations of the transfec-
tants and their respective controls were either 100 nM
(miRNA mimic) or 150 nM (siRNAs). After 4 h, transfec-
tion medium was replaced by fresh cell culture medium
and cells were incubated for another 48 h. For further ana-
lyses cells were then harvested by trypsin/EDTA treatment.
RNA isolation and cDNA synthesis
RNA was isolated from cells using peqGOLD TriFast
(Peqlab) and from tissue cryosections either using Invi-
sorb Spin Tissue RNA Mini Kit (Invitek; for subsequent
mRNA analysis) or peqGOLD TriFast (for subsequent
miRNA analysis) according to the manufacturers’ recom-
mendations. For mRNA analysis in tissues and cells, re-
verse transcription of 500 ng RNA into cDNA was carried
out using SuperScript II Reverse Transcriptase (Life Tech-
nologies) and random hexamer primers (GE Healthcare)
according to the manufacturers’ recommendations. For
miRNA analysis in tissue samples, a total of 400 ng RNA
was reverse transcribed into cDNA using the TaqMan
MicroRNA Reverse Transcription Kit and Megaplex RT
Primers (Human Pool A; both Life Technologies) which
allows for reverse transcription of up to 381 miRNAs in a
single reaction.
Quantitative polymerase chain reaction (qPCR)
Gene expression of AMACR, EZH2, PSGR, PSMA and
TRPM8 as well as of the reference gene TBP (TATA box
binding protein) was measured by qPCR using the Light-
Cycler FastStart DNA Master Hybridization Probes Kit
and the LightCycler 1.5 instrument (both Roche). Primers
and probes are listed in Additional file 1: Table S2; qPCR
conditions are summarized in Additional file 1: Table S3.
The mRNA copy number of a single marker was calculated
in relation to the amplification product amounts of exter-
nal standards as described previously [3]. All qPCR mea-
surements were carried out at least twice as independent
PCR runs for each cDNA sample. Samples were measured
for a third time if differences of >30% occurred. The means
of all measurements were used for further calculations.
Relative expression levels of PCa related markers were ob-
tained by normalization to the reference gene TBP.
The expression of the selected miRNAs was quantified
by miRNA-specific TaqMan MicroRNA Assays (Life Tech-
nologies) according to the manufacturer’s instructions
using the TaqMan Gene Expression Master Mix and the
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file 1: Table S3). The following TaqMan MicroRNA Assays
were used: 002253 (hsa-miR-101), 002284 (hsa-miR-138),
002285 (hsa-miR-186), 002099 (hsa-miR-224), 000405 (hsa-
miR-26a), 000407 (hsa-miR-26b), 000563 (hsa-miR-374a),
001274 (hsa-miR-410), 001515 (hsa-miR-660) and 001006
for the reference RNA (RNU48). RNU48 was selected for
normalization purposes due to its reported biological
stability and its usefulness as a reference molecule for
miRNA expression analyses in PCa and other cancer tis-
sues [41-43]. Automatic second derivative analysis was
applied for the determination of the crossing points
(CP). Each CP was determined twice in independent
qPCR runs and the mean value was used for further calcu-
lations. If the mean deviation of both CP values exceeded
0.25, a third measurement was done and included in the
calculation of the mean. Standard curves were used to de-
termine the copy number of a single miRNA. Relative
expression levels of the miRNAs were obtained by nor-
malization to the reference RNA RNU48.
In tissue samples the fold expressions of PCa-associated
genes as well as of miRNAs were determined relative to
the median relative expression in Tf or BPH tissues. For
transfection experiments the fold expressions were calcu-
lated using the ΔΔCP method.
Heat map generation
Heat map generation was carried out using the Genesis
software package. Relative expression data were log-
transformed and fully normalized for genes and miRNAs.
Western Blot analysis
Protein separation and subsequent Western blotting were
performed as described previously [44]. Membranes were
probed with primary antibodies against AMACR (1:1000;
Cell Signaling, clone 2A10), EZH2 (1:750; Cell Signaling,
clone AC22) and α-tubulin (1:5000; Calbiochem, clone
DM1A); the latter served as a loading control. The sec-
ondary polyclonal rabbit anti-mouse immunoglobulin
HRP-linked antibody (1:1000; Dako, P0260) as well as the
Enhanced Chemiluminescence Kit (GE Healthcare) were
used for visualization. Quantification of the protein con-
tent was performed by means of computer-assisted video-
densitometry (Quantity One Basic, Bio-Rad).
Construction of plasmid vectors and luciferase reporter assay
A putative binding site of miR-26a within the 3′UTR
of AMACR was identified using the target prediction
tool of microRNA.org (Additional file 1: Table S1). To con-
struct luciferase reporter vectors, oligonucleotides (Bio-
mers) comprising the wildtype or mutated binding site
were inserted downstream of the Firefly luciferase gene
into the pmir-GLO Dual-Luciferase miRNATarget Expres-
sion Vector (Promega) according to the manufacturer’sinstructions. The insert regions in the vectors were se-
quenced (GATC Biotech) to verify incorporation of the
respective target sequence. The resulting vectors are re-
ferred to as pmir-GLO-A26a (AMACR-specific miRNA-
26a-binding sequence; AAC ACA CTG AGG AGA TAC
TTG AA) and pmir-GLO-Amut26a (mutated AMACR-
specific miRNA-26a-binding sequence; AAC ACA CTG
AGG CGA GAC CCA AA). Nucleotides in bold indi-
cate changes introduced within the target sequence to
generate the mutant form.
For luciferase reporter assays, DU-145 cells were cul-
tured in 24-well plates and co-transfected with 1.5 μg of
the indicated vector and 100 nM of miR-26a mimic or
miR-CON using Lipofectamine 2000 (final concentration
20 ng/μl; Life Technologies) for 24 h. Following incuba-
tion with fresh cell culture medium for another 24 h,
cells were lysed and analyzed for luciferase activity using
the Dual-Glo Luciferase Assay System (Promega) and a
Mithras LB 940 Multimode Microplate Reader (Berthold)
according to the manufacturers’ instructions. Following
background adjustment, Firefly luciferase activity was nor-
malized to Renilla luciferase activity. The normalized lu-
ciferase activity was then compared to that of the pmir-
GLO-A26a vector co-transfected with miR-CON. For
each transfection, luciferase activity was averaged from
three replicates.
Statistics
Statistical analyses were carried out with the PASW Sta-
tistics 18.0.0 (SPSS) software. Correlations were assessed
by Spearman’s rank correlation coefficients. Group com-
parisons were conducted as indicated. A p value <0.05 was
defined to be statistically significant; p < 0.1 was consid-
ered as a statistical trend.
Results
Up-regulation of PCa-associated genes
The expression levels of the PCa-associated genes AMACR,
EZH2, PSGR, PSMA, and TRPM8 were analyzed in 50 Tu
and corresponding Tf prostate tissue specimens as well
as in 30 BPH tissue samples. The median expression levels
of all genes were significantly higher in Tu tissue com-
pared to either control group with median fold expres-
sions ranging from +1.61 to +19.36 versus Tf tissue and
from +3.02 to +36.65 versus BPH tissue (Table 2). The
tissue type-dependent expression of the genes was further
highlighted in a heat map (Additional file 1: Figure S1),
whereupon the clearest expression differences could be
seen between Tu and BPH tissues. The highest relative
transcript level was observed for AMACR and the lowest
for EZH2 regardless of the tissue specimen subset. Com-
pared to either control tissue the highest up-regulation in
Tu tissue was detected for AMACR (+19.36 vs Tf; +36.65
vs BPH), whereas the lowest was observed for EZH2 (+1.61
Table 2 Differentially expressed genes between malignant and non-malignant prostate tissues samples
Gene Median relative transcript levels Median fold expressions
Tu Tf BPH Tu vs Tf[median] Tu vs BPH[median]
(n = 50) (n = 50) (n = 30)
AMACR 2093.38 108.14 57.12 +19.36** +36.65**
EZH2 0.93 0.58 0.31 +1.61** +3.02**
PSGR 44.70 16.72 2.45 +2.67** +18.23**
PSMA 28.02 11.47 1.88 +2.44** +14.91**
TRPM8 36.58 13.44 4.01 +2.72** +9.12**
Depicted are the median relative transcript levels of the PCa-associated genes (normalized to TBP) in Tu, matched Tf and BPH tissue samples as well as the median
fold expressions of the Tu samples compared to the indicated control group. P values were calculated by the Mann–Whitney U test with a two-sided 95%
confidence interval (**p < 0.01).
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samples with an unaltered, up-regulated or down-regulated
fold expression compared to either control group was eval-
uated for each gene (Additional file 1: Table S4). For this
purpose a fold expression of ≥2.0 was considered as up-
regulation and of ≤ −2.0 as down-regulation, whereas the
remaining fraction was regarded as an unaltered expression.
Compared to Tf samples, more than 40% of the Tu samples
showed an up-regulation for each gene with the highest
rate of up-regulation (80%) for AMACR. A down-regulated
or unaltered expression was observed for 2-18% and 10-
58% of the Tu samples, respectively. Compared to the BPH
group, 80-90% of the Tu samples showed an up-regulation
of the respective genes, whereas only minor proportions
(≤20%) exhibited an unaltered or diminished expression.
Identification of putative miRNA regulators for PCa-
associated genes
In silico miRNA prediction identified numerous putative
miRNA regulators for each PCa-associated gene. The
resulting miRNA pool was then filtered for possibly rele-
vant miRNAs according to the aforementioned selection
criteria. In this manner, nine candidate miRNAs were
selected from the entire miRNA pool for subsequent
qPCR analyses (Table 3): hsa-miR-101, -138, -186, -224,
-26a, -26b, -374a, -410 and -660. The most frequent pre-
dictions were observed for miR-101, miR-138, miR-26a
and miR-26b for EZH2.
Down-regulation of selected miRNAs in PCa tissues
The expression levels of these nine miRNAs were then
determined in the same sample cohort used for the gene
expression analyses. Due to loss of tissue during process-
ing only 46 Tf tissue specimens were available for the
miRNA expression analyses. The median expression levels
of all miRNAs were lower in Tu tissue compared to Tf
and BPH tissue (Table 4). This was further emphasized in
a heat map based on the relative miRNA expression in
the various prostate tissue specimens (Additional file 1:
Figure S1), whereupon the most distinct expressiondifferences occurred between Tu and BPH tissue samples.
The lowest relative transcript level was observed for miR-
410 and the highest for miR-26a in all tissue subsets. For
all miRNAs the tumor-specific down-regulation was sta-
tistically significant compared to Tf tissue samples with
median fold expressions ranging from -1.35 to -5.61. Ex-
cept for miR-101 and miR-26b the observed decrease in
expression was also significant when compared to BPH
tissue samples with median fold expressions ranging from
-1.17 to -5.49. Compared to either control tissue the high-
est down-regulation in Tu tissue was detected for miR-
138 (-5.61 vs Tf; -5.49 vs BPH), while the lowest ratio of
down-regulation was observed for miR-26b (-1.35 vs Tf;
-1.17 vs BPH). The proportions of Tu samples with an un-
altered, up-regulated or down-regulated fold expression
compared to either control group are summarized in
Additional file 1: Table S4. Compared to Tf samples, a
high percentage of down-regulation (54-86%) was ob-
served for most of the miRNAs except for miR-101
(44%), miR-26b (32%) and miR-660 (38%). Only minor
fractions of the Tu samples (≤10%) showed an up-
regulation. Depending on the miRNA the fraction of Tu
samples with an unaltered expression was 14-60%.
Compared to the BPH samples, the lowest proportions
of down-regulated Tu samples were observed for miR-
101 (26%) and miR-26b (24%). For the other miRNAs
the distributions of fold expression did not shift at all or
shifted only marginally from the distribution pattern com-
pared to the Tf group. The highest down-regulation rate
compared to either control group was observed for miR-
186 with none of the Tu samples showing an up-regulation.
Expression levels of PCa-associated genes and selected
miRNAs depending on clinicopathological parameters
Furthermore, the relative transcript levels of the relevant
genes as well as of the selected miRNAs were compared
with regard to the different clinicopathological parame-
ters. With the exception of TRPM8 none of the relevant
genes showed a significant association with age, serum
PSA concentration, tumor stage, Gleason score or initial
Table 3 Results of the in silico analyses and the Spearman rank correlation
miRNA Target gene
AMACR EZH2 PSGR PSMA TRPM8
miR-101 8x
−0.156#
miR-138 1x 7x
−0.256** −0.215*
miR-186 2x 4x
−0.551** −0.418**
miR-224 4x
−0.384**
miR-26a 1x 6x 1x 3x
−0.335** −0.383** −0.237** −0.362**
miR-26b 1x 6x 3x
−0.154# −0.141 −0.107
miR-374a 2x 3x 3x
−0.230** −0.248** −0.329**
miR-410 1x 1x 2x 2x 1x
−0.273** −0.293** −0.283** −0.239** −0.395**
miR-660 3x 3x
−0.241** −0.289**
In the upper rows the respective numbers of predictions out of eight possible algorithms are denoted. In the lower rows results of the Spearman rank correlation
expressed as Spearman correlation coefficients are displayed. The relative transcript levels of the target genes and the miRNAs in all tissue samples (Tu, Tf, BPH)
were used for the calculation of the Spearman correlation coefficients. Empty cells indicate that there was no prediction by any algorithm in the in silico analyses.
*p < 0.05, **p < 0.01, #p < 0.1 (statistical trend).
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Solely the expression of TRPM8 was with 25.14 significantly
lower in patients with nonorgan-confined tumors (pT3 + 4,
n = 27) compared to organ-confined tumors (pT2, n = 23)
with 52.44 (p = 0.03) (Additional file 1: Table S5).
Regarding the expression of the selected miRNAs in
relation to the clinicopathological parameters significant
associations were only observed for miR-186. The relativeTable 4 Differentially expressed miRNAs between malignant
miRNA Median relative transcript levels (x10-3)
Tu Tf
(n = 50) (n = 46)
miR-101 1.52 2.91
miR-138 0.19 1.08
miR-186 39.52 138.59
miR-224 1.19 4.12
miR-26a 179.04 380.81
miR-26b 51.77 69.98
miR-374a 17.63 39.65
miR-410 0.08 0.28
miR-660 13.46 22.50
Depicted are the median relative transcript levels of the evaluated miRNAs (normal
median fold expressions of the Tu samples compared to the indicated control grou
confidence interval (*p < 0.05, **p < 0.01).expression of miR-186 was with 33.89×10-3 signifi-
cantly lower in nonorgan-confined tumors (pT3 + 4, n =
27) compared to organ-confined tumors (pT2, n = 23) with
47.70×10-3 (p = 0.028; Figure 1A & Additional file 1: Table
S6). Patients with initial metastases (N+/M+, n = 10) dis-
played also a significantly lower transcript level of miR-186
than patients without any initial metastases (N0M0, n = 40):
44.86×10-3 for N0M0 vs 31.18×10-3 for N+/M+, p = 0.005and non-malignant prostate tissues samples
Median fold expressions
BPH Tu vs Tf[median] Tu vs BPH[median]
(n = 30)
2.01 −1.92** −1.32
1.06 −5.61** −5.49**
160.43 −3.51** −4.06**
3.22 −3.45** −2.70**
310.84 −2.13** −1.74**
60.60 −1.35 * −1.17
33.84 −2.25** −1.92**
0.33 −3.64** −4.29**
22.63 −1.67** −1.68**
ized to RNU48) in Tu, matched Tf and BPH tissue samples as well as the
p. P values were calculated by the Mann–Whitney U test with a two-sided 95%
pT2 pT3+4 N0M0 N+/M+
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Figure 1 Relative transcript levels of miR-186 in PCa samples with regard to clinicopathological parameters. (A) Comparison of the miR-
186 expression levels in organ-confined (pT2, n = 23) versus nonorgan-confined tumors (pT3 + 4, n = 27). (B) Comparison of the miR-186 expres-
sion levels in patient samples without any initial metastases (N0M0, n = 40) versus those with initial metastases (N+/M+, n = 10). Transcript levels
of miR-186 were normalized to RNU48. P values were calculated by the Mann–Whitney U test with a two-sided 95% confidence interval. Outliers
are indicated by circles; extreme values are indicated by asterisks.
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associations were observed between the expression of any
miRNA and age, serum PSA concentration or Gleason
score (Additional file 1: Table S6). However, the transcript
levels of miR-138 and miR-224 were also frequently lower
albeit not significantly in tumors that were more aggressive
or in an advanced disease stage (Additional file 1: Table S6).
Furthermore, the expression of miR-26a, miR-374a and
miR-410 gradually decreased with increasing Gleason score
(Additional file 1: Table S6).
Correlation between the expression of PCa-associated
genes and their putative miRNA regulators
A possible correlation between the expression of the se-
lected miRNAs and of their putative target genes was ana-
lyzed by Spearman rank correlation using the expression
data gained from all tissue specimens (50 Tu, 46 Tf, 30
BPH). The expression levels of specific miRNAs showed
weak to moderate inverse correlations with the expression
levels of their putative target genes. The Spearman correl-
ation coefficients (rs) ranged from -0.107 to -0.551 (Table 3).
Except for miR-101 and miR-26b these correlations were
statistically significant. However, a statistical trend was
found for the combinations miR-101/EZH2 (rs = -0.156,
p = 0.081) and miR-26b/AMACR (rs = -0.154, p = 0.086).
Overall, the strongest correlations with the expression of
their putative target genes were observed for miR-186,
miR-26a and miR-224 (Table 3).
Exemplary scatter plots based on the matched miRNA
and target gene expression in all three tissue subsets are
shown in Figure 2 for the combinations miR-186/AMACR(rs = -0.551, p < 0.01), miR-186/PSMA (rs = -0.418, p <
0.01), miR-26a/TRPM8 (rs = -0.362, p < 0.01) and miR-
26a/EZH2 (rs = -0.383, p < 0.01). These scatter plots dem-
onstrate that tumor tissues (Tu: red dots) exhibited a
higher expression of the relevant genes which in turn was
associated with a rather low miRNA expression. In con-
trast, a high miRNA expression in the non-malignant con-
trol groups (Tf: green dots; BPH: blue dots) was linked to
a lower expression of the relevant genes. This pattern of
differential miRNA/gene expression was also observed for
all the other predicted miRNA/gene combinations in the
scatter plots (data not shown).
Effects of exogenous miR-26a on the expression of
selected target genes in PCa cell lines
Among the miRNAs studied here, miR-26a has already
been identified as a direct regulator of EZH2 [36,38]. In
the present study, miR-26a was also recognized as a pu-
tative regulator of AMACR. AMACR and to a smaller
extent EZH2 are strongly expressed in the PCa cell lines
DU-145, PC-3 and LNCap (data not shown). Further-
more, miR-26a was detectable in all three cell lines with
DU-145 cells exhibiting the lowest expression of this
miRNA (Table 5).
In order to determine if miR-26a can influence the ex-
pression of its potential target genes AMACR and EZH2
PCa cells were transiently transfected with a miR-26a
mimic. Specific siRNAs targeting AMACR or EZH2 were
used as positive controls for the inhibition of the gene ex-
pression. Incubation of all three cells lines with the specific
siRNAs led to notable reductions of the respective mRNA
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http://www.biomedcentral.com/1471-2407/14/82and protein levels (Figures 3 and 4). The siRNA against
AMACR even produced a complete down-regulation of the
AMACR protein in DU-145 and PC-3 cells.
Following exogenous administration of the miR-26a
mimic a significant increase of this miRNA was observed
in all three cell lines (Table 5). An over-expression of miR-
26a diminished the AMACR transcript and protein level
by about 20-60% and 20-50%, respectively, depending onTable 5 Transcript expression of miR-26a in PCa cell lines
Treatment M
DU-145
Untreated 35.1 ± 12.3
miR-CON (100 nM) 36.6 ± 14.4
miR-26a (100 nM) 30895.2 ± 13836.0α,β
The data represent the mean relative transcript levels of miR-26a (normalized to RN
cells or following treatment with 100 nM miR-26a mimic or miR-CON. P values were
vs untreated, βp < 0.05 vs miR-CON).the cell line (Figure 3A, Figure 4A, C). In contrast, treat-
ment with the mimic for miR-26a did not produce a dis-
tinct inhibition of EZH2 mRNA and protein expression in
any cell line (Figure 3B and 4B).
Direct regulation of AMACR by miR-26a
To determine whether miR-26a can directly target the
3′UTR of AMACR, we studied the effects of the miR-edian relative transcript levels (x10-3)
PC-3 LNCap
44.0 ± 29.8 66.7 ± 37.1
33.2 ± 23.1 52.2 ± 36.3
16047.6 ± 13441.3α,β 11042.1 ± 6940.7α,β
U48) of five independent experiments with their mean deviation in untreated
calculated by the Mann–Whitney U test with Bonferroni correction (αp < 0.05
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Figure 3 Effect of miR-26a mimic and siRNAs on target gene mRNA expression in PCa cell lines. Transcript levels of (A) AMACR and (B)
EZH2 were determined by qPCR and normalized to TBP. Normalized values are shown relative to the corresponding control treatments (100%):
miR-CON (100 nM) for treatment with miR-26a mimic and siR-CON (150 nM) for treatment with siRNAs, respectively. Values represent averages of
two to five independent experiments with their mean deviation. A one-tailed paired t-test was used to compare differences between cells treated
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http://www.biomedcentral.com/1471-2407/14/8226a mimic on a luciferase reporter vector containing the
putative binding site for miR-26a within the 3′UTR of
AMACR. The alignment of miR-26a with its putative
target sequence within the human AMACR 3′UTR is
depicted in Figure 5A. Since DU-145 cells exhibited the
lowest expression of miR-26a, this cell line was used for
the luciferase reporter assay. Co-transfection of DU-145
cells with the miR-26a mimic and the luciferase reporter
vector containing the wildtype AMACR binding site led
to a significant decrease in luciferase activity by about 40%
compared to the control treatment (Figure 5B). There was
no significant reduction in luciferase activity following co-
transfection with miR-26a mimic and the luciferase re-
porter vector containing the mutated AMACR binding
site (Figure 5B), thereby confirming that miR-26a can dir-
ectly target AMACR.
Discussion
It is widely accepted that oncogenesis and tumor pro-
gression is initiated through a deregulated expression of
certain genes which then leads to the malignant trans-
formation of the affected cells. In previous studies we
have shown that genes such as AMACR, EZH2, PSGR,
PSMA and TRPM8 are tumor-specifically up-regulated
in PCa compared to benign tissue and thus, could be
used for diagnostic purposes [3-6], whereupon the ob-
served PCa-specific up-regulation of the relevant genes
was comparable to those in the present study. Conse-
quently, the elevated expression of the aforementioned
genes can deeply impact the growth and survival of PCa
cells eventually resulting in oncogenesis and/or tumorprogression [9,11,13,22,45]. Therefore, such PCa-associated
genes could represent suitable diagnostic tools as well as
promising targets for the therapeutic intervention. How-
ever, the identification and characterization of the under-
lying mechanisms for the deregulation of these molecular
markers are crucial for the understanding of the biology
and clinical course of the disease. The demonstrated ab-
normal expression patterns could be associated with a
deregulation of miRNAs which serve as post-transcriptional
regulators of their target gene expression [23,24]. In accord-
ance, miRNAs are aberrantly expressed in several types of
cancers [25-27] and thus, could influence oncogenesis and
tumor progression via an altered miRNA-target gene-
interaction. Using in silico analyses nine miRNAs (miR-
101, -138, -186, -224, -26a, -26b, -374a, -410, -660), which
could potentially regulate the expression of the PCa-
associated genes, have been selected for further analysis.
By using a qPCR approach it was revealed that the se-
lected miRNAs are down-regulated in PCa compared to
matched non-malignant tissue or BPH, respectively. Sev-
eral studies have also demonstrated distinct miRNA ex-
pression profiles for PCa compared to normal prostate
tissue [25,28-33]. However, a comparison of the studies
by Ambs et al. [28], Volinia et al. [25] and Porkka et al.
[30] showed that there are no overlapping subsets be-
tween the differentially expressed miRNAs analyzed in
these studies [46]. The observed inconsistencies can
mainly be attributed to different methods of tissue collec-
tion, RNA isolation and miRNA detection [47]. Therefore,
a consensus on PCa-specific miRNA alterations has not
been established to date.
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http://www.biomedcentral.com/1471-2407/14/82The above mentioned discrepancies have also been ob-
served for some of the miRNAs evaluated in this study. To
begin with, some studies demonstrated a down-regulation
for miR-101 [31], miR-224 [29], miR-26a [30], miR-26b
[30] and miR-410 [28] in primary PCa samples compared
to normal prostate tissue which is consistent with our re-
sults. In contrast to our data and to some of the aforemen-
tioned profiling studies, up-regulated expression levels in
PCa tissues have been demonstrated for miR-101 [32],
miR-26a [25,28] and miR-26b [31]. However, the results of
the cited profiling studies were obtained by microarray or
deep sequencing analysis and have not been validated by
qPCR with the only exception of miR-26a which was con-
firmed to be up-regulated in a small subset of 10 prostatic
tumors [28].
In agreement with our results and also based on an as-
sessment by qPCR, a significant down-regulation in primary
PCa compared to benign samples was noted for miR-101
[40], miR-26a [38] and miR-224 [43], whereas miR-26b wasonly diminished by trend [38]. In a small sample cohort,
miR-138 was up-regulated in high grade tumors (Gleason
score ≥8; n = 14) versus normal epithelium (n = 10), which
is contradictory to our results [33]. Upon reviewing the
current literature miR-186, miR-374a and miR-660 have
not been demonstrated to be differentially expressed in pri-
mary PCa compared to benign prostate tissue to date.
Therefore, this is the first study reporting that miR-186,
miR-374a and miR-660 are significantly down-regulated in
primary PCa compared with benign samples.
Furthermore, none of the profiling studies evaluated
associations of the particular miRNAs with clinicopatholog-
ical parameters or has further analyzed them with regard to
the regulation of potential target genes [25,28-32]. Only in
the qPCR-based study by Mavridis et al., miR-224 expres-
sion was reported to be gradually decreased as Gleason
score and tumor stage progressed and also to be associated
with a favorable prognosis [43]. In the present study, the
miR-224 transcript levels were also frequently lower albeit
AB
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http://www.biomedcentral.com/1471-2407/14/82not significantly in tumors that were more aggressive or in
an advanced disease stage. Eventually, a significant associ-
ation with clinicopathological features was only observed
for miR-186. A decreased miR-186 expression was signifi-
cantly linked to more aggressive and advanced tumors indi-
cating that down-regulation of miR-186 in PCa could be a
factor of disease progression.
The present study also demonstrated that the deregu-
lation of the miRNAs is linked to an increase of the
transcript levels of their putative target genes. Except for
miR-101 and miR-26b the expression levels of the evalu-
ated miRNAs showed significantly weak to moderate
inverse correlations with the expression levels of their
putative target genes. Among the miRNAs included in
this study miR-101 [36,40], miR-138 [37,39], miR-26a
[36,38] and miR-26b [38] are of particular interest as
some studies have already identified EZH2 as one of
their direct target genes. This was also reflected here by
the high prediction rate of these miRNAs for EZH2 in
the in silico analyses. The link between these miRNAs
and EZH2 has been demonstrated in numerous experi-
mental settings amongst others investigating the import-
ance of this regulatory mechanism for the onset and
progression of various types of cancer including PCa. In
various PCa cell lines, over-expression of miR-101, miR-
26a and miR-26b could lead to repression of both EZH2
mRNA and protein as well as to a reduced cellularproliferation suggesting a tumor-suppressive function for
these miRNAs in PCa [36,38,40].
For some initial continuative analysis, we focused on
miR-26a as this miRNA has already been identified as a
direct regulator of EZH2 in PCa [36,38]. Moreover, the
down-regulated expression of miR-26a in clinical PCa
samples has been shown to be significantly inversely cor-
related with EZH2 levels with a Spearman correlation
coefficient of -0.516 (p = 0.0013) [38]. In the present study,
there was also a significant inverse correlation between the
expression of EZH2 and miR-26a (rs = -0.383, p < 0.01).
The differences between the two studies might be partly
explained by the use of different sample cohorts. Koh
et al. analyzed the expression of miR-26a and EZH2 in 36
prostate samples (18 Tu, 18 Tf) [38], whereas we con-
ducted the expression analyses in a larger cohort of 126
prostate tissue samples (50 Tu, 46 Tf, 30 BPH) and thus,
may have gained a higher statistical reliability. However, in
the present study, miR-26a failed to decrease EZH2 when
administered exogenously to PCa cells. This finding is
similar to the results reported by the study of Cao et al. in
which miR-26a reduced EZH2 protein levels only in DU-
145 cells [36]. In contrast, Koh et al. reported that over-
expression of miR-26a repressed both EZH2 mRNA and
protein in DU-145, PC-3 and LNCap cells [38]. The au-
thors attributed this discrepancy to methodical differences
which cannot be excluded.
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http://www.biomedcentral.com/1471-2407/14/82In addition to EZH2, AMACR was also identified as a
target gene possibly regulated by miR-26a. The putative
link between AMACR and miR-26a was reflected by
a moderate inverse correlation of their expression levels
in prostate tissue (rs = -0.335, p < 0.01). In vitro results
gathered in this study demonstrated that miR-26a can
potently repress the mRNA and protein expression of
AMACR depending on the cell line. A direct regulatory
effect of miR-26a on the newly identified target gene
AMACR was confirmed by luciferase reporter assay. Co-
transfection of DU-145 cells with the miR-26a mimic
and the luciferase reporter vector containing the wild-
type AMACR binding site produced a decrease in lucif-
erase activity by about 40%, whereas co-transfection
with the luciferase reporter vector containing the mu-
tated AMACR binding site did not lead to a reduction in
luciferase activity. Taken together, this is the first study
showing that the expression of AMACR can directly be
regulated by a miRNA.
Overall, this is the first study that demonstrated potential
interactions between the PCa-associated genes AMACR,
PSGR, PSMA and TRPM8 and specific miRNAs. Notably,
strong correlations were also observed between miR-186
and its putative target genes AMACR and PSMA as well
as between miR-224 and its proposed target gene AMACR.
Further research is warranted to confirm a direct regula-
tory effect of these miRNAs on their potential target genes.
Conclusions
In conclusion, this study demonstrated that the expression
of specific miRNAs is decreased in PCa and inversely
correlates with the up-regulation of their putative target
genes. Consequently, miRNAs could contribute to onco-
genesis and progression of PCa via an altered miRNA-
target gene-interaction. A preliminary in vitro assessment
showed that exogenous administration of miR-26a re-
sulted in a decreased expression of AMACR mRNA and
protein depending on the cell line. By using a luciferase
reporter assay, AMACR was confirmed as a direct target
of miR-26a.
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Additional file 1: Figure S1. Heat map based on the relative
expression of genes and miRNAs in human prostate tissue. Columns
represent genes and miRNAs; rows represent prostate tissue samples (red
squares: Tu samples, green squares: Tf samples, yellow squares: BPH
samples). Transcript levels of genes and miRNAs were normalized to TBP
and RNU48, respectively. Table S1. Web addresses of the bioinformatics
resources used for miRNA prediction. Table S2. Sequences of primers
and probes used for qPCR. Table S3. Conditions for qPCR measurements.
Table S4. Distributions of fold expressions of PCa genes and miRNAs in
prostate cancer. Depicted are the proportions of fold expression in Tu
samples compared to either Tf or BPH samples. A fold expression of ≥2.0
was considered as up-regulation and of ≤ −2.0 as down-regulation,
whereas the remaining proportion was regarded as an unalteredexpression. Table S5. Expression of selected genes in prostate cancer
dependent on clinicopathological parameters. Depicted are median
relative transcript levels of the evaluated genes (normalized to TBP) in Tu
tissue samples. A Mann–Whitney U test with a two-sided 95% confidence
interval was used for two group comparisons. Three-group comparisons
were carried out by the Kruskal–Wallis test followed by a Mann–Whitney
U test with a two-sided 95% confidence interval for post hoc analyses.
Significant differences are highlighted in bold. Table S6. Expression of
selected miRNAs in prostate cancer dependent on clinicopathological
parameters. Depicted are median relative transcript levels of the evaluated
miRNAs (normalized to RNU48) in Tu tissue samples. A Mann–Whitney U
test with a two-sided 95% confidence interval was used for two group
comparisons. Three-group comparisons were carried out by the
Kruskal–Wallis test followed by a Mann–Whitney U test with a two-sided
95% confidence interval for post hoc analyses. Significant differences are
highlighted in bold.
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